<DOC>
	<DOCNO>NCT01013259</DOCNO>
	<brief_summary>Due worldwide increase prevalence allergic rhinoconjunctivitis , new therapeutical strategy need . The symptomatic treatment topical systemic antihistamine corticosteroid often insufficient . E.coli Nissle 1917 immunomodulatory capacity reveal less side effect . E.coli Nissle 1917 sedative property exhibit hepatotoxic quality . Thus , E.coli Nissle 1917 represent new relevant therapeutical agent .</brief_summary>
	<brief_title>Immunomodulation E.Coli Nissle 1917 Patients With Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>clinical relevant grass pollen allergy require treatment since 2 year positive skin prick test grass positive sIgE towards grass ( CAP 2 ) write informed consent perennial rhinoconjunctivitis sinusitis chronic diarrhoea exist severe gastrointestinal disease current specific immunotherapy grass pollen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>E.coli</keyword>
	<keyword>Mutaflor</keyword>
	<keyword>grass pollen</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>rhinoconjunctivitis cause grass pollen</keyword>
</DOC>